| 1 |
Xu S, Foss F. New nonchemotherapy treatment options for cutaneous T-cell lymphomas. Expert Rev Anticancer Ther 2021;21:1017-28. [PMID: 33554707 DOI: 10.1080/14737140.2021.1882859] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 2 |
Lee YP, Yoon SE, Song Y, Kim SJ, Yoon DH, Chen TY, Koh YI, Kang KW, Lee HS, Wei KTK, Lim ST, Poon M, Irawan C, Zhao W, Do YR, Lee MH, Ng SC, Lee WS, Guo Y, Zhang H, Kang HJ, Yun HJ, Kim HJ, Lung DTC, Kwak JY, Han JJ, Mun YC, Oh SY, Shim H, Kwon JH, Sohn BS, Park SK, Jo JC, Ko YH, Jun Z, Kim WS. Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. Int J Hematol 2021;114:355-62. [PMID: 34302593 DOI: 10.1007/s12185-021-03179-7] [Reference Citation Analysis]
|
| 3 |
Frederiks AJ, Creeper KJ, Spagnolo DV, Cannell P, Radeski D. Complete remission of stage IV erythrodermic mycosis fungoides with large cell transformation through combination of pralatrexate and romidepsin followed by allogeneic hematopoietic stem cell transplantation. Australas J Dermatol 2021;62:e400-3. [PMID: 34028795 DOI: 10.1111/ajd.13606] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 4 |
Pavlidis A, Piperi C, Papadavid E. Novel therapeutic approaches for cutaneous T cell lymphomas. Expert Rev Clin Immunol 2021;17:629-41. [PMID: 33890833 DOI: 10.1080/1744666X.2021.1919085] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 5 |
Ospina‐idárraga JA, Martinez‐cordero RH, Enciso‐olivera LJ, Idrobo‐quintero H. The Role of Autologous Stem‐cell Transplantation in Peripheral T‐cell Lymphomas. The Peripheral T‐Cell Lymphomas 2021. [DOI: 10.1002/9781119671336.ch22] [Reference Citation Analysis]
|
| 6 |
Habault J, Thonnart N, Pasquereau-Kotula E, Bagot M, Bensussan A, Villoutreix BO, Marie-Cardine A, Poyet JL. PAK1-Dependent Antitumor Effect of AAC-11‒Derived Peptides on Sézary Syndrome Malignant CD4+ T Lymphocytes. J Invest Dermatol 2021;141:2261-2271.e5. [PMID: 33745910 DOI: 10.1016/j.jid.2021.01.033] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 7 |
Pujol R, Gallardo F. Cutaneous Lymphomas — Part I: Mycosis Fungoides, Sézary Syndrome, and CD30+ Cutaneous Lymphoproliferative Disorders. Actas Dermo-Sifiliográficas (English Edition) 2021;112:14-23. [DOI: 10.1016/j.adengl.2020.12.003] [Reference Citation Analysis]
|
| 8 |
Willemze R, Theurich S, Schlaak M. Indolent Cutaneous T-Cell Lymphomas. Hematologic Malignancies 2021. [DOI: 10.1007/978-3-030-55989-2_14] [Reference Citation Analysis]
|
| 9 |
Pujol R, Gallardo F. Linfomas cutáneos. Parte I: micosis fungoide, síndrome de Sézary y proliferaciones linfoides cutáneas CD30 positivas. Actas Dermo-Sifiliográficas 2021;112:14-23. [DOI: 10.1016/j.ad.2020.08.003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 10 |
Scarisbrick JJ, Bagot M, Ortiz-Romero PL. The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma. Br J Haematol 2021;192:683-96. [PMID: 33095448 DOI: 10.1111/bjh.17117] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 11 |
Seidl-philipp M, Nguyen VA. New systemic treatment options in mycosis fungoides and Sézary syndrome. memo 2020;13:280-284. [DOI: 10.1007/s12254-020-00618-9] [Reference Citation Analysis]
|
| 12 |
Sézary syndrome. Skin Lymphoma 2020. [DOI: 10.1002/9781119485933.ch4] [Reference Citation Analysis]
|
| 13 |
Dimitriou F, Schanz U, Nair G, Kimeswenger S, Brüggen MC, Hoetzenecker W, French LE, Dummer R, Cozzio A, Guenova E. Long-Term Disease Control After Allogeneic Hematopoietic Stem Cell Transplantation in Primary Cutaneous T-Cell Lymphoma; Results From a Single Institution Analysis. Front Med (Lausanne) 2020;7:290. [PMID: 32714935 DOI: 10.3389/fmed.2020.00290] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 14 |
Pratt M, Glassman SJ. Complete response of refractory mycosis fungoides to treatment of pancreatic cancer with combination gemcitabine and nab-paclitaxel: A possible new regimen for the treatment of advanced cutaneous T-cell lymphoma. JAAD Case Rep 2020;6:581-3. [PMID: 32685643 DOI: 10.1016/j.jdcr.2020.05.013] [Reference Citation Analysis]
|
| 15 |
. Mycosis fungoides. Skin Lymphoma. Wiley; 2020. pp. 23-112. [DOI: 10.1002/9781119485933.ch3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 16 |
Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M; ESMO Guidelines Committee. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018;29:iv30-40. [PMID: 29878045 DOI: 10.1093/annonc/mdy133] [Cited by in Crossref: 105] [Cited by in F6Publishing: 111] [Article Influence: 26.3] [Reference Citation Analysis]
|
| 17 |
de Masson A, O'Malley JT, Elco CP, Garcia SS, Divito SJ, Lowry EL, Tawa M, Fisher DC, Devlin PM, Teague JE, Leboeuf NR, Kirsch IR, Robins H, Clark RA, Kupper TS. High-throughput sequencing of the T cell receptor β gene identifies aggressive early-stage mycosis fungoides. Sci Transl Med 2018;10:eaar5894. [PMID: 29743350 DOI: 10.1126/scitranslmed.aar5894] [Cited by in Crossref: 69] [Cited by in F6Publishing: 67] [Article Influence: 17.3] [Reference Citation Analysis]
|
| 18 |
Oka T, Miyagaki T. Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome. Front Med (Lausanne) 2019;6:116. [PMID: 31192214 DOI: 10.3389/fmed.2019.00116] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 19 |
Denis D, Beneton N, Laribi K, Maillard H. Management of mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL): focus on chlormethine gel. Cancer Manag Res 2019;11:2241-51. [PMID: 30962713 DOI: 10.2147/CMAR.S138661] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
|
| 20 |
Wain T, Venning VL, Consuegra G, Fernandez‐peñas P, Wells J. Management of cutaneous T‐cell lymphomas: Established and emergent therapies. Australas J Dermatol 2019;60:200-8. [DOI: 10.1111/ajd.13011] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
|
| 21 |
Dereure O. [Primary skin lymphomas: Current therapy]. Ann Dermatol Venereol 2019;146:92-9. [PMID: 30709635 DOI: 10.1016/j.annder.2018.11.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 22 |
Zain J. Transplantation. Cancer Treatment and Research 2019. [DOI: 10.1007/978-3-319-99716-2_13] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 23 |
Demina OM, Akilov OE, Rumyantsev AG. Cutaneous T-cell lymphomas: modern data of pathogenesis, clinics and therapy. Onkogematologiâ 2018;13:25-38. [DOI: 10.17650/1818-8346-2018-13-3-25-38] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 24 |
Fountain E, Mistry H, Jain P, Duvic M, Fowler N. Response to pembrolizumab and lenalidomide in advanced refractory mycosis fungoides. Leuk Lymphoma 2019;60:1079-82. [PMID: 30301395 DOI: 10.1080/10428194.2018.1516879] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 25 |
Hosoi H, Hatanaka K, Murata S, Mushino T, Kuriyama K, Nishikawa A, Hanaoka N, Tamura S, Nakakuma H, Sonoki T. Long-term complete remission of early hematological relapse after discontinuation of immunosuppressants following allogeneic transplantation for Sezary syndrome. Hematol Rep 2018;10:7497. [PMID: 30283619 DOI: 10.4081/hr.2018.7497] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
|
| 26 |
Dulmage BO, Kong BY, Holzem K, Guitart J. What Is New in CTCL—Pathogenesis, Diagnosis, and Treatments. Curr Derm Rep 2018;7:91-8. [DOI: 10.1007/s13671-018-0214-0] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
|
| 27 |
Chung CG, Poligone B, Heald PW. Cutaneous T-Cell Lymphoma. Biologic and Systemic Agents in Dermatology 2018. [DOI: 10.1007/978-3-319-66884-0_33] [Reference Citation Analysis]
|
| 28 |
van Santen S, Vermeer MH, Willemze R. Classification and recommended treatment options for folliculotropic mycosis fungoides. Expert Opinion on Orphan Drugs 2017;6:35-45. [DOI: 10.1080/21678707.2018.1406796] [Reference Citation Analysis]
|
| 29 |
Stranzenbach R, Theurich S, Schlaak M. [Role of stem cell transplantation in treatment of primary cutaneous T‑cell lymphoma]. Hautarzt 2017;68:716-20. [PMID: 28785925 DOI: 10.1007/s00105-017-4023-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
|
| 30 |
Heitmiller K, Barnes J, Chen ST. Cutaneous Lymphoma—Inpatient Considerations. Curr Derm Rep 2017;6:63-76. [DOI: 10.1007/s13671-017-0173-x] [Reference Citation Analysis]
|
| 31 |
Trautinger F, Eder J, Assaf C, Bagot M, Cozzio A, Dummer R, Gniadecki R, Klemke C, Ortiz-romero PL, Papadavid E, Pimpinelli N, Quaglino P, Ranki A, Scarisbrick J, Stadler R, Väkevä L, Vermeer MH, Whittaker S, Willemze R, Knobler R. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome – Update 2017. European Journal of Cancer 2017;77:57-74. [DOI: 10.1016/j.ejca.2017.02.027] [Cited by in Crossref: 260] [Cited by in F6Publishing: 202] [Article Influence: 43.3] [Reference Citation Analysis]
|
| 32 |
Bagherani N, Smoller BR. An overview of cutaneous T cell lymphomas. F1000Res 2016;5:F1000 Faculty Rev-1882. [PMID: 27540476 DOI: 10.12688/f1000research.8829.1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 50] [Article Influence: 6.6] [Reference Citation Analysis]
|
